Immune-mediated Colitis – An Update for Surgeons
Authors:
Open Access
- 1 July 2025
- journal article
- Published by Wolters Kluwer Health in World Journal of Colorectal Surgery
- Vol. 14 (3) , 85-93
Abstract
This narrative review aims to examine the current literature on medical and surgical treatment approaches for immune-mediated colitis (IMC), and propose a novel surgical algorithm for managing IMC in cases refractory to medical treatment. A comprehensive literature search was conducted to identify studies evaluating surgical interventions for IMC in patients receiving immune checkpoint inhibitors. Of the 464 studies identified, 28 met the inclusion criteria following analysis. IMC-related complications, as well as medical and surgical treatment methods for IMC, were collated and analyzed. A total of 28 papers reported on 1141 cases of IMC, of which 62 required surgical intervention. Sixty-two percent of the patients who required surgical intervention either failed medical treatment or developed perforation during medical treatment for IMC. The majority of these patients underwent colectomy. In addition, two fecal microbiome transplantation (FMT) were successfully performed for IMC, resulting in the resolution of symptoms. Management should begin with medical therapy alongside early concomitant surgical consultation. In patients who fail medical therapy, the role of rescue diverting loop ileostomy should be considered over initiating third-line medical therapies, due to the narrow window of opportunity to preserve intestinal continuity and achieve resolution of colitis. FMT may represent a novel adjunctive strategy for steroid-refractory IMC.Keywords
This publication has 37 references indexed in Scilit:
- A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortiumESMO Open, 2024
- Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitorsClinics and Research in Hepatology and Gastroenterology, 2024
- Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCUGastroenterología y Hepatología, 2024
- From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor ColitisDigestive Diseases and Sciences, 2021
- Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacionalGastroenterología y Hepatología, 2021
- Epstein-Barr Virus-Positive Mucocutaneous Ulcers Complicate Colitis Caused by Immune Checkpoint Regulator Therapy and Associate With Colon PerforationClinical Gastroenterology and Hepatology, 2020
- Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom controlCancer Medicine, 2019
- Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to managementNature Reviews Gastroenterology & Hepatology, 2018
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- J ileal pouch–anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patientsBritish Journal of Surgery, 1998